Market closedNon-fractional
Mural Oncology plc/MURA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
Ticker
MURA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Dublin, Ireland
Employees
119
Website
www.muraloncology.com
MURA Metrics
BasicAdvanced
$59M
Market cap
-
P/E ratio
-$11.48
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$59M
Financial strength
Current ratio
11.269
Quick ratio
11.022
Long term debt to equity
3.12
Total debt to equity
5.741
Management effectiveness
Return on equity (TTM)
-179.96%
Valuation
Price to book
0.25
Price to tangible book (TTM)
0.25
Price to free cash flow (TTM)
-0.323
Growth
Earnings per share change (TTM)
0.32%
What the Analysts think about MURA
Analyst Ratings
Majority rating from 1 analysts.
MURA Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$31M
-48.07%
Profit margin
0.00%
NaN%
MURA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 24
Q2 24
Actual
-$1.84
-
Expected
-$2.66
-$1.90
Surprise
-30.83%
-
MURA News
AllArticlesVideos
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
GlobeNewsWire·2 months ago
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mural Oncology plc stock?
Mural Oncology plc (MURA) has a market cap of $59M as of July 27, 2024.
What is the P/E ratio for Mural Oncology plc stock?
The price to earnings (P/E) ratio for Mural Oncology plc (MURA) stock is 0 as of July 27, 2024.
Does Mural Oncology plc stock pay dividends?
No, Mural Oncology plc (MURA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Mural Oncology plc dividend payment date?
Mural Oncology plc (MURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Mural Oncology plc?
Mural Oncology plc (MURA) does not currently have a Beta indicator.
Buy or sell Mural Oncology plc stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.